Did You Know...
...that Kleenex tissue was originally designed to be a gas mask filter? It was developed at the beginning of World War I to replace cotton, which was then in short supply as a surgical dressing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7985428 | Method and composition for modulation of systemic inflammatory responses syndrome (SIRS) The present invention relates to pharmaceutical composition comprising animal venom and using same in a method for the treatment of Systemic Inflammatory Response Syndrome (SIRS) and related pathologies. ... | 07/26/2011 |
| 7758894 | Modified elapid venoms as stimulators of the immune reaction Detoxified cobra venom and its constituent neurotoxins have been reported to have potent antiviral activity. Others have reported that snake venoms were generally immune stimulants. Recent research has revealed more specific details on the effects of detoxified veno... | 07/20/2010 |
| 7223730 | Antithrombosis enzyme from the snake venom of agkistrodon acutus This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof. ... | 05/29/2007 |
| 7182028 | System and method for the pyrolization of waste A system for the pyrolization of waste has a combustion chamber with a fuel inlet and a hot gas outlet, a pyrolization chamber separated from the combustion chamber, and a conveyor means positioned within the pyrolization chamber for moving waste from the waste inle... | 02/27/2007 |
| 7056887 | Treatment of acute coronary syndrome with GLP-1 The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of an exendin-4 molecule. The exendin-4 can ... | 06/06/2006 |
| 7018659 | Anti-arrhythmic pharmaceutical composition and a process thereof The present invention relates to an anti arrhythmic pharmaceutical comprising effective amount of compound designated as KCV-CAF obtained from the venom of Indian snake King Cobra Ophiophagus hannah and optionally pharmaceutically acceptable ingredients and a... | 03/28/2006 |
| 6833131 | Antivenom immunesera An antivenom comprising a mixture of monospecific antisera each raised against venoms of one species or sub-species is disclosed. Also disclosed is a pharmaceutical composition comprising the antivenom of the invention, and a method of treating envenomation in a mam... | 12/21/2004 |
| 6613324 | Adhesive for the gluing of biological tissues Disclosed is an adhesive for gluing of biological tissue, in particular human body tissue. The adhesive contains fibrinogen, a substance capable of supplying calcium ions, blood-coagulating factor XIIIa and, as a fibrinogen-splitting substance, a snake-ve... | 09/02/2003 |
| 6489451 | Antithrombosis enzyme from the snake venom of agkistrodon acutus This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof.... | 12/03/2002 |
| 6399576 | Method of inhibiting apoptosis A method of inhibiting apoptosis, comprising administering an effective ingredient batroxobin.... | 06/04/2002 |
| 6106830 | Methods for the treatment of apoptosis-related diseases by batroxobin A pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases which comprises as an effective ingredient batroxobin.... | 08/22/2000 |
| 5904922 | Treatment with polyvalent antivenom containing immunoglobulin which is greater than 50% venom-reactive Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for treatment of humans and animals, and for analytical use. Polyvalent antivenoms are produced containing immunoglobulin which is greater than fifty percent venom reactive. Purified... | 05/18/1999 |
| 5869044 | Method for the treatment or prophylaxis of ischemia-reperfusion injury Medicaments for the treatment or prophylaxis of ischemia-reperfusion injury in myocardial ischemia and cerebral ischemia, characterized in that the medicament contains batroxobin as an effective component.... | 02/09/1999 |
| 5817309 | Antidote for hirudin and synthetic thrombin inhibitors and method of use The invention relates to an antidote for hirudin and synthetic thrombin inhibitors; the antidote contains a compound that splits prothrombin into meizothrombin, a prothrombin intermediate, a pharmacologically acceptable salt thereof or a mixture of these ... | 10/06/1998 |
| 5705198 | Test for lupus anticoagulant It was found that the use of a phospholipid dependent prothrombin activator purified from the venom of snakes belonging to the Elapidae family, especially members of the Oxyaranus and Psuedonaja genera is most useful in tests for the determination of Lupu... | 01/06/1998 |
| 5695751 | Enhancing delivery of large neutral amino acid drugs L-amino acid oxidase is utilized to reduce the plasma level of large neutral amino acids to allow the opportunity of increased large neutral amino acid drug transport across the blood brain barrier. Preferably anti L-amino acid oxidase antibody is adminis... | 12/09/1997 |
| 5679350 | Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material A method of delivering a medicament to the surface of a cancer cell and transferring the medicament into the cancer cell using an activated plasminogen activator material such as a plasminogen activator inhibitor type-1 or type-2 (PAI-1, PAI-2). The medic... | 10/21/1997 |
| 5676974 | Pharmaceutical compositions containing giroxina and phospholipase A2 and methods of increasing a patient's CD4 count using the pharmaceutical compositions Pharmaceutical compositions for treatment of humans suffering from the symptoms of acquired immune deficiency syndrome (AIDS) or its precursors, lymphadenopathy syndrome (LAS) or AIDS-related complex (ARC) or secondary diseases relating thereto and other ... | 10/14/1997 |
| 5562907 | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins Human-derived or human-compatible antitoxins are administered is an adjunct to therapy with a toxin, such as botulinum toxin or an immunotoxin, or as an adjunct to therapy with a combination of toxins, in order to reduce or prevent endogenous production o... | 10/08/1996 |
| 5562899 | Medical prevention of lacerations to the vagina and perineum A common complication of vaginal delivery is the tearing of the muscles of the vagina and perineum. This tearing results in an irregular laceration which the surgeon must then repair. Current obstetrical practice is to prevent this irregular laceration by... | 10/08/1996 |
| 5453370 | Method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes A method for the preparation of a phospholipid-dependent prothrombin activator from the venom of snakes belonging to the Elapidae family, the activator comprising an increased plasma clotting activity in the presence of phospholipids and calcium ions; a r... | 09/26/1995 |
| 5232911 | Mixture of a non-covalent heterodimer complex and a basic amphiphatic peptide as cytotoxic agent Novel cytotoxic agent useful against malignant tumors. It provides a stable composition of matter based on the cytotoxic activity of two synergistically acting toxins which sequence are herein described. The basic amphipathic peptide binds to the cell mem... | 08/03/1993 |
| 5178864 | Lipoprotein removal by soluble enzymes A therapeutically effective amount of soluble phospholipase A2 is administered into a subject for lowering the low density lipoproteins ("LDL") in the blood. Phospholipase A2 modifies the plasma LDL by hydrolyzing the phospholipids p... | 01/12/1993 |
| 5164196 | Crotoxin complex as cytotoxic agent The present invention provides a stable composition of matter based on the cytotoxic activity of a basic phospholipase A2 of molecular weight 14,500 and isoelectric point 9.6-9.7 (crotoxin B) isolated from the venom of Crotalus durissus terrifi... | 11/17/1992 |
| 5013555 | Agent for desensitizing man and/or animals against an allergen An agent for desensitization of man and/or animals against an allergen comprising liposomes that comprise the allergen is provided together with a method for inducing desensitization by administration of the agent.... | 05/07/1991 |
| 5006512 | Therapeutic usages of inhibitors for a potassium efflux channel The invention provides novel therapeutic usages of inhibitors of a potassium channel of the cells. Since the increase of the intracellular calcium concentration is known to trigger various reactions which destroy the cells, the prevention of calcium entry... | 04/09/1991 |
| 4849403 | Protein C activator, methods of preparation and use thereof A method and composition for assaying protein C is described. The method comprises reacting a protein C-containing medium with a protein C-activating activator preparation obtained from venom of the snake Agkistrodon contortrix, or venom of another snake ... | 07/18/1989 |
| 4806346 | Method for isolation of antigen specific immunoglobulin A process for preparing the purified F(ab)2 fragment of equine Ig(T) from horses hyperimmunized with snake venom which comprises: (a) passing crude diluted hyperimmune equine serum contianing snake venom antigen specific Ig(T) buffered to an acidic ... | 02/21/1989 |
| 4741902 | Compositions for treatment of neurological and related disorders The invention provides compositions of matter having pharmacological activity and which are useful in the treatment of the symptoms of neurological and other disorders, particularly those disorders which are caused by malfunction of the immune mechanism. ... | 05/03/1988 |
| 4610879 | Fibrinolytic enzyme from snake vernom A protease moiety having direct fibrinolytic activity which is useful in thrombolytic therapy is isolated from snake venom and shown to comprise a metalloproteinase having a molecular weight of from 25 to 27 kd and an isoelectric point of about 6.5 to 7.0... | 09/09/1986 |
| 4585653 | Neuraminidase treated ancrod Disclosed is a pharmaceutically effective agent and method of use, comprising ancrod which has been incubated with neuraminidase. The neuraminidase-treated ancrod (NTA) can be substituted for ancrod in ancrod therapy, when immunological resistance to the ... | 04/29/1986 |
| 4350625 | Substance with fibrinolytic activity and method of manufacturing the same This invention relates to a new fibrinolytic substance and the method of manufacturing the same which can be singly isolated from venom of venomous snakes belonging to the family of Trimeresurus taxonomically by means of molecular sieve chromatography and... | 09/21/1982 |
| 4341762 | Use of snake venoms for treatment of neurological and related disorders The present invention provides stable compositions of matter including venoms and/or venom fractions extracted from various elapid and viperid snakes, the present compositions of matter having pharmacological activity and being further useful in treating ... | 07/27/1982 |
| 4292308 | Treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents A method is provided for treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents. The animals are injected with an effective amount of modified neurotoxin, preferably intramuscularly or intravenously, either... | 09/29/1981 |
| 4162303 | Potency and atoxicity test for modified neurotoxin A method for proving the potency and atoxicity of modified neurotoxin is provided. A thin sheet of viable cells is provided on a growth substrate. Viability of the sheet of cells is defined as exhibiting an uninhibited growth potential of at least 10... | 07/24/1979 |
| 4154656 | Method for determining the fibrinogen content of physiological liquid What is disclosed is an enzyme system cleaving fibrinogen, said system comprising a fibrinogenase and a water-soluble polysaccharide.... | 05/15/1979 |
| 4145185 | Reagents for screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in blood plasmas Screening tests and bioassay of von Willebrand's factor (platelet aggregating factor) in human and animal blood plasma are effected using a reagent of blood platelets and snake venom having a positive platelet aggregating cofactor effect. The reagent and ... | 03/20/1979 |
| 4126676 | Modified neurotoxin derived from Naja genus snake venom The present invention relates to a composition, a process of production thereof, and a method for treatment of neurological diseases, and especially to the treatment of such diseases as amyotropic lateral sclerosis, by administering detoxified but neurotr... | 11/21/1978 |
| 4027012 | Process for the extraction of components having anticoagulant activity "in vivo" from snake venoms and products obtained A process for extracting and isolating from snake venoms the enzymatic component having "in vitro" coagulant activity and "in vivo" anticoagulant activity from the other components having "in vitro" coagulant activity and from the protein components, wher... | 05/31/1977 |
| 4012502 | Snake venom inhibitor material and method of purification A material extracted from snakes such as snake serum is purified to obtain an inhibitor for snake venom toxicity and/or proteolytic enzymes. Snake serum is treated to obtain a useful therapeutic agent present in the serum and attached to a high molecular ... | 03/15/1977 |
